WebJan 6, 2024 · These results are consistent with the SELECT-EARLY Japanese sub-analysis, in which significant improvements were observed across primary (including radiographic) and secondary endpoints with upadacitinib 15 mg and 30 mg monotherapy versus methotrexate in methotrexate-naïve patients, with no additional benefits with the 30 mg … WebUpadacitinib, sold under the brand name Rinvoq, is a Janus kinase ... to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY)" at ClinicalTrials.gov; Clinical trial number NCT02706951 for "A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate ...
New Long-Term Data from Upadacitinib Phase 3 Studies in …
WebJul 8, 2024 · The SELECT-EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with … WebJun 12, 2024 · NORTH CHICAGO, Ill., June 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily (15 mg or 30 mg, SELECT-EARLY; 15 mg plus … blooming news columbia minerva
A Study to Evaluate the Efficacy and Safety of Upadacitinib in ...
WebJan 26, 2024 · Upadacitinib inhibits structural joint damage progression in RA; Fatigue prevalent and persistent even in early RA; Pain and functional impairment affect sleep quality in RA; Interstitial lung disease is prevalent in patients with RA and tied to shorter survival; Filgotinib: A promising option across different patient populations with RA WebJun 2, 2024 · SELECT-COMPARE is a Phase 3, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy of RINVOQ compared to placebo and HUMIRA in adult patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX and continued a stable background of MTX. WebMay 4, 2024 · SELECT-EARLY comprised two periods: a 48-week, double-blind, active-comparator-controlled phase followed by an open-label, long-term extension period of up to 4 years ( Figure 1 ). In the global study, 947 patients were randomized 1:1:1 to receive either upadacitinib (15 or 30 mg qd as monotherapy) or weekly MTX [ 18 ]. free download movies app for pc